title: The use of intravitreal bevacizumab in neovascular glaucoma: a case report.
abstract: OBJECTIVE
  To assess the short-term safety and efficacy of an intravitreal injection of bevacizumab in a patient with neovascular glaucoma.
  
  
  METHODS
  Intravitreal bevacizumab injection was given in a patient with neovascular glaucoma and the changes in the visual acuity, intraocular pressure (lOP), iris neovascularisation were noted before injection and after one day, one week, three weeks and six weeks. Regression of the iris new vessels and normalization of the intraocular pressure was noted.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab was effective and safe in the short-term in a patient with neovascular glaucoma. It may be a useful adjunctive treatment.
authors: National Institute of Ophthalmology, Pune, India.
authors: A S
authors: AS
authors: Kelkar
authors: S B
authors: SB
authors: Kelkar
authors: J A
authors: JA
authors: Kelkar
authors: M
authors: M
authors: Nagpal
authors: S P
authors: SP
authors: Patil
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000150:complications; D008297:Male; D012074:Remission Induction
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab